Narnatumab
Based on 1 Customer Validation
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.90%
- CAS. Nr.: 1188275-92-4
- Molecular Weight:145.8 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG1 kappa
Human
MSPR/RON/CD136
Narnatumab (100 nM; 24 h) inhibits MSP-induced migration of human lung and breast cancer cell lines[1].
Narnatumab inhibits the MSP-induced mitogenic response of a pancreatic cancer cell line[1].
Narnatumab (0.01-100 nM; pretreatment for 1 h) blocks ligand-induced receptor phosphorylation and downstream signaling molecules phosphorylation in RON-expressing tumor cells and in a RON-transfected cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Narnatumab exhibits terminal half-life (t1/2=5.2 d) and achieves antitumor effects at a steady-state plasma trough level of approximately 140 μg/mL in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells[1]
-
Dosage:2, 20, 60 mg/kg
-
Administration:I.p. every 3 days for 36 and 18 days
-
Result:Inhibited tumor growth in a dose-dependent manner.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized RON/MSPR Protein, Human (HEK293, His, HY-P77180) can bind Narnatumab. The EC50 for this effect is 0.756 ng/mL. -
Flow Cytometry analysis of A431 cells labelling MSPR/RON/CD136 (red) with Narnatumab (anti-MSPR/RON/CD136) (HY-P99375). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS. Nr. 1188275-92-4
-
Appearance Liquid
-
Molecular Weight 145.8 kDa
-
Color Colorless to light yellow
-
SMILES
[Narnatumab]
-
Synonyms
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (259 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Narnatumab Related Classifications
HY-P99375 Related Classifications
Powered by Bioz